Loss of function of PTEN alters the relationship between glucose concentration and cell proliferation, increases glycolysis, and sensitizes cells to 2-deoxyglucose

Cancer Letters

Volumn 289, Issue 2, 2010, Pages 246-253

  Blouin, Marie José ^a   Zhao, Yunhua ^a   Zakikhani, Mahvash ^a   Algire, Carolyn ^a   Piura, Esther ^a   Pollak, Michael ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

2 Deoxyglucose; Glioma; Glucose; Glycolysis; PTEN

Indexed keywords

DEOXYGLUCOSE; GLUCOSE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ARTICLE; CELL CYCLE; CELL ENERGY; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENERGY METABOLISM; GLIOMA CELL; GLUCOSE INTAKE; GLYCOLYSIS; HUMAN; HUMAN CELL; HYPERGLYCEMIA; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RISK FACTOR;

ANTIMETABOLITES; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL CYCLE; CELL PROLIFERATION; DEOXYGLUCOSE; FLOW CYTOMETRY; GLIOMA; GLUCOSE; GLYCOLYSIS; HUMANS; OXYGEN CONSUMPTION; PTEN PHOSPHOHYDROLASE; TUMOR CELLS, CULTURED;

EID: 76849111682     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.08.021     Document Type: Article

References (40)

1. Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S.I., Puc J., Miliaresis C., Rodgers L., McCombie R., Bigner S.H., Giovanella B.C., Ittmann M., Tycko B., Hibshoosh H., Wigler M.H., and Parsons R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275 (1997) 1943-1947
2. Knobbe C.B., Lapin V., Suzuki A., and Mak T.W. The roles of PTEN in development, physiology and tumorigenesis in mouse models: a tissue-by-tissue survey. Oncogene 27 (2008) 5398-5415
3. Carracedo A., and Pandolfi P.P. The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene 27 (2008) 5527-5541
4. Wong J.T., Kim P.T., Peacock J.W., Yau T.Y., Mui A.L., Chung S.W., Sossi V., Doudet D., Green D., Ruth T.J., Parsons R., Verchere C.B., and Ong C.J. Pten (phosphatase and tensin homologue gene) haploinsufficiency promotes insulin hypersensitivity. Diabetologia 50 (2007) 395-403
5. Hsu P.P., and Sabatini D.M. Cancer cell metabolism: Warburg and beyond. Cell 134 (2008) 703-707
6. Warburg O. On respiratory impairment in cancer cells. Science 124 (1956) 269-270
7. Tang X., Powelka A.M., Soriano N.A., Czech M.P., and Guilherme A. PTEN, but not SHIP2, suppresses insulin signaling through the phosphatidylinositol 3-kinase/Akt pathway in 3T3-L1 adipocytes. J. Biol. Chem. 280 (2005) 22523-22529
8. Ono H., Katagiri H., Funaki M., Anai M., Inukai K., Fukushima Y., Sakoda H., Ogihara T., Onishi Y., Fujishiro M., Kikuchi M., Oka Y., and Asano T. Regulation of phosphoinositide metabolism, Akt phosphorylation, and glucose transport by PTEN (phosphatase and tensin homolog deleted on chromosome 10) in 3T3-L1 adipocytes. Mol. Endocrinol. 15 (2001) 1411-1422
9. Radu A., Neubauer V., Akagi T., Hanafusa H., and Georgescu M.M. PTEN induces cell cycle arrest by decreasing the level and nuclear localization of cyclin D1. Mol. Cell Biol. 23 (2003) 6139-6149
10. Gray T.K., Mohan S., Linkhart T.A., and Baylink D.J. Estradiol stimulates in vitro the secretion of insulin-like growth factors by the clonal osteoblastic cell line, UMR106. Biochem. Biophys. Res. Commun. 158 (1992) 407-412
11. Blake D.A., and McLean N.V. A colorimetric assay for the measurement of D-glucose consumption by cultured cells. Anal. Biochem. 177 (1989) 156-160
12. Asano T., Shibasaki Y., Ohno S., Taira H., Lin J.L., Kasuga M., Kanazawa Y., Akanuma Y., Takaku F., and Oka Y. Rabbit brain glucose transporter responds to insulin when expressed in insulin-sensitive Chinese hamster ovary cells. J. Biol. Chem. 264 (1989) 3416-3420
13. Wu M., Neilson A., Swift A.L., Moran R., Tamagnine J., Parslow D., Armistead S., Lemire K., Orrell J., Teich J., Chomicz S., and Ferrick D.A. Multiparameter metabolic analysis reveals a close link between attenuated mitochondrial bioenergetic function and enhanced glycolysis dependency in human tumor cells. Am. J. Physiol. Cell Physiol. 292 (2007) C125-C136
14. Shaw R.J. Glucose metabolism and cancer. Curr. Opin. Cell Biol. 18 (2006) 598-608
15. DeBerardinis R.J., Lum J.J., Hatzivassiliou G., and Thompson C.B. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 7 (2008) 11-20
16. Kroemer G., and Pouyssegur J. Tumor cell metabolism: cancer's Achilles′ heel. Cancer Cell 13 (2008) 472-482
17. Levitt R.J., Georgescu M.M., and Pollak M. PTEN-induction in U251 glioma cells decreases the expression of insulin-like growth factor binding protein-2. Biochem. Biophys. Res. Commun. 336 (2005) 1056-1061
18. Pelicano H., Martin D.S., Xu R.H., and Huang P. Glycolysis inhibition for anticancer treatment. Oncogene 25 (2006) 4633-4646
19. Tagg S.L., Foster P.A., Leese M.P., Potter B.V., Reed M.J., Purohit A., and Newman S.P. 2-Methoxyoestradiol-3,17-O,O-bis-sulphamate and 2-deoxy-D-glucose in combination: a potential treatment for breast and prostate cancer. Brit. J. Cancer 99 (2008) 1842-1848
20. Zhu Z., Jiang W., McGinley J.N., and Thompson H.J. 2-Deoxyglucose as an energy restriction mimetic agent: effects on mammary carcinogenesis and on mammary tumor cell growth in vitro. Cancer Res. 65 (2005) 7023-7030
21. Law J.H., Habibi G., Hu K., Masoudi H., Wang M.Y.C., Stratford A.L., Park E., Gee J.M.W., Finlay P., Jones H.E., Nicholson R.I., Pollak M., and Dunn S.E. Phosphorylated insulin-like growth factor-1/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res. 68 (2008) 10238-10246
22. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat. Rev. Cancer 8 (2008) 915-928
23. Elstrom R.L., Bauer D.E., Buzzai M., Karnauskas R., Harris M.H., Plas D.R., Zhuang H., Cinalli R.M., Alavi A., Rudin C.M., and Thompson C.B. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res. 64 (2004) 3892-3899
24. Nussey S.S., and Whitehead S.A. The endocrine pancreas. In: Nussey S.S., and Whitehead S.A. (Eds). Endocrinology: An Integrated Approach (2001), Taylor & Francis, London
25. Blanco-Aparicio C., Renner O., Leal J.F., and Carnero A. PTEN, more than the AKT pathway. Carcinogenesis 28 (2007) 1379-1386
26. Cheng J.Q., Altomare D.A., Klein M.A., Lee W.C., Kruh G.D., Lissy N.A., and Testa J.R. Transforming activity and mitosis-related expression of the AKT2 oncogene: evidence suggesting a link between cell cycle regulation and oncogenesis. Oncogene 14 (1997) 2793-2801
27. Gesbert F., Sellers W.R., Signoretti S., Loda M., and Griffin J.D. BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-kinase/AKT pathway. J. Biol. Chem. 275 (2000) 39223-39230
28. Brandts C.H., Sargin B., Rode M., Biermann C., Lindtner B., Schwable J., Buerger H., Muller-Tidow C., Choudhary C., McMahon M., Berdel W.E., and Serve H. Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation. Cancer Res. 65 (2005) 9643-9650
29. Robey R.B., and Hay N. Is Akt the "Warburg kinase"?-Akt-energy metabolism interactions and oncogenesis. Semin. Cancer Biol. 19 (2009) 25-31
30. Ortega A.D., Sanchez-Arago M., Giner-Sanchez D., Sanchez-Cenizo L., Willers I., and Cuezva J.M. Glucose avidity of carcinomas. Cancer Lett. 276 (2009) 125-135
31. Guppy M., Leedman P., Zu X., and Russell V. Contribution by different fuels and metabolic pathways to the total ATP turnover of proliferating MCF-7 breast cancer cells. Biochem. J. 364 (2002) 309-315
32. Moreno-Sanchez R., Rodriguez-Enriquez S., Marin-Hernandez A., and Saavedra E. Energy metabolism in tumor cells. FEBS J. 274 (2007) 1393-1418
33. Algire C., Zakikhani M., Blouin M.-J., Shuai J.H., and Pollak M. Metformin attenuates the stimulatory effect of a high energy diet on in vivo H59 carcinoma growth. Endocr. Relat. Cancer 15 (2008) 833-839
34. Venkateswaran V., Haddad A.Q., Fleshner N.E., Fan R., Sugar L.M., Nam R., Klotz L.H., and Pollak M. Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts. J. Nat. Cancer Inst. 99 (2007) 1793-1800
35. Ma J., Li H., Giovannucci E., Mucci L., Qiu W., Nguyen P., Gaziano J.M., Pollak M., and Stampfer M. Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol. 9 (2008) 1039-1047
36. Jee S.H., Ohrr H., Sull J.W., Yun J.E., Ji M., and Samet J.M. Fasting serum glucose level and cancer risk in Korean men and women. JAMA 293 (2005) 194-202
37. Saydah S.H., Loria C.M., Eberhardt M.S., and Brancati F.L. Abnormal glucose tolerance and the risk of cancer death in the United States. Am. J. Epidemiol. 157 (2003) 1092-1100
38. Stattin P., Bjor O., Ferrari P., Lukanova A., Lenner P., Lindahl B., Hallmans G., and Kaaks R. Prospective study of hyperglycemia and cancer risk. Diabetes Care 30 (2007) 561-567
39. Wolpin B.M., Meyerhardt J.A., Chan A.T., Ng K., Chan J.A., Wu K., Pollak M.N., Giovannucci E.L., and Fuchs C.S. Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer. J. Clin. Oncol. 27 (2008) 176-185
40. Richardson L.C., and Pollack L.A. Therapy insight: influence of type 2 diabetes on the development, treatment and outcomes of cancer. Nat. Clin. Pract. Oncol. 2 (2005) 48-53